Regulatory T cells in gastrointestinal tumors

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 4, 2011, Pages 489-501

  Raghavan, Sukanya ^a   Quiding Jädierbrink, Marianne ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

chemokines; FoxP3; gastrointestinal tumors; immune suppression; immunotherapy; regulatory T cells; TGF ; Tregs

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 35; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BIOACCUMULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; COLON CARCINOMA; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONDYLOMA ACUMINATUM; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; EFFECTOR CELL; ESOPHAGUS CANCER; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH TUMOR; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH3 CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MICE; RATS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 79960764022     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.44     Document Type: Review

References (161)

1. + T cells. Eur. J. Immunol. 33(3), 579-587 (2003). (Pubitemid 36367661)
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995).
3. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18(5), 723-737 (1970).
4. +CD25high regulatory cells in human peripheral blood. J. Immunol. 167(3), 1245-1253 (2001). (Pubitemid 32703119)
5. + T cells in thymus, cord and adult blood. Immunology 106(2), 190-199 (2002). (Pubitemid 34621827)
6. + regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003). (Pubitemid 36432314)
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003). (Pubitemid 36222930)
8. Brunkow ME, Jeffery EW, Hjerrild KA et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68-73 (2001). (Pubitemid 32044521)
9. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001). (Pubitemid 32044513)
10. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16(2), 311-323 (2002). (Pubitemid 34211969)
11. + T cells. J. Immunol. 172(12), 7306-7314 (2004). (Pubitemid 38747590)
12. + regulatory T cell function. Science 322(5899), 271-275 (2008).
13. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3(2), 135-142 (2002). (Pubitemid 34141443)
14. + T cells. J. Immunol. 173(8), 5008-5020 (2004). (Pubitemid 39387783)
15. Tone M, Tone Y, Adams E et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl Acad. Sci. USA 100(25), 15059-15064 (2003). (Pubitemid 37518016)
16. Cote AL, Zhang P, O'Sullivan JA et al. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J. Immunol. 186(1), 275-283 (2011).
17. Yamaguchi T, Hirota K, Nagahama K et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27(1), 145-159 (2007). (Pubitemid 47089022)
18. Becher D, Deutscher ME, Simpfendorfer KR et al. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur. J. Immunol. 40(10), 2778-2790 (2010).
19. Wohlfert E, Belkaid Y. Role of endogenous and induced regulatory T cells during infections. J. Clin. Immunol. 28(6), 707-715 (2008).
20. + regulatory T-cell activation and expansion. J Allergy Clin. Immunol. 123(4), 749-755; quiz 756-747 (2009).
21. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32 (2001). (Pubitemid 33070205)
22. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. 202(7), 901-906 (2005). (Pubitemid 41396890)
23. Wirnsberger G, Hinterberger M, Klein L. Regulatory T-cell differentiation versus clonal deletion of autoreactive thymocytes. Immunol. Cell Biol. 89(1), 45-53 (2011).
24. + T regulatory cells. J. Immunol. 184(7), 3433-3441 (2010).
25. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652), 737-742 (1997). (Pubitemid 27458961)
26. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28-50 (2006). (Pubitemid 44116698)
27. + and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 8(9), 931-941 (2007). (Pubitemid 47300007)
28. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 75(2), 263-274 (1993). (Pubitemid 23320290)
29. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179(2), 589-600 (1994).
30. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190(7), 995-1004 (1999).
31. Chen Y, Inobe J, Weiner HL. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol. 178(1), 62-68 (1997). (Pubitemid 27250280)
32. Sporn MB, Roberts AB. Transforming growth factor-b: recent progress and new challenges. J. Cell Biol. 119(5), 1017-1021 (1992).
33. + regulatory T cells. J. Immunol. 177(11), 7634-7644 (2006). (Pubitemid 44846278)
34. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin. Immunol. 123(1), 18-29 (2007). (Pubitemid 46401504)
35. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198(12), 1875-1886 (2003). (Pubitemid 38032120)
36. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{b}. J. Immunol. 174(3), 1446-1455 (2005).
37. Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T cell function. Eur. J. Immunol. 38(4), 915-917 (2008).
38. + dendritic cells display unique functional properties that are conserved between mice and humans. J. Exp. Med. 205(9), 2139-2149 (2008).
39. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J. Clin. Invest. 117(1), 60-69 (2007).
40. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340(11), 825-831 (1999). (Pubitemid 29142625)
41. Ekbom A. Risk of cancer in ulcerative colitis. J. Gastrointest. Surg. 2(4), 312-313 (1998). (Pubitemid 128423114)
42. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
43. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66(2), 605-612 (2006). (Pubitemid 43165918)
44. Cursiefen C, Chen L, Borges LP et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113(7), 1040-1050 (2004). (Pubitemid 38544126)
45. Schoppmann SF, Birner P, Stockl J et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161(3), 947-956 (2002). (Pubitemid 34988382)
46. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18(5), 349-355 (2008).
47. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008). (Pubitemid 351430364)
48. + T cells. Gastroenterology 135(1), 234-243 (2008). (Pubitemid 351899008)
49. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
50. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12(18), 5423-5434 (2006). (Pubitemid 44497257)
51. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13(3), 902-911 (2007). (Pubitemid 46340366)
52. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328-2339 (2007). (Pubitemid 46890865)
53. + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107(12), 2866-2872 (2006). (Pubitemid 44937041)
54. + regulatory T cells. Clin. Cancer Res. 14(8), 2413-2420 (2008). (Pubitemid 351551075)
55. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5), 1089-1099 (2003). (Pubitemid 37022112)
56. Enarsson K, Lundgren A, Kindlund B et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin. Immunol. 121(3), 358-368 (2006). (Pubitemid 44738715)
57. + ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 136(10), 1585-1595 (2010).
58. + regulatory T cells is associated with clinical behaviour in gastric cancer. Br. J. Cancer 98(1), 148-153 (2008).
59. Yuan XL, Chen L, Li MX et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol. 134(3), 277-288 (2010).
60. +CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55(9), 1064-1071 (2006). (Pubitemid 43800721)
61. Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 69(20), 7895-7898 (2009).
62. Xue L, Lu HQ, He J et al. Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data. Dis. Esophagus 23(4), 340-346 (2010).
63. Maruyama T, Kono K, Izawa S et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis. Esophagus 23(5), 422-429 (2010).
64. Zingg U, Montani M, Frey DM et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur. J. Surg. Oncol. 36(7), 670-677 (2010).
65. Zingg U, Montani M, Frey DM, Dirnhofer S, Went P, Oertli D. Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. Eur. J. Surg. Oncol. 35(12), 1268-1272 (2009).
66. Yoshioka T, Miyamoto M, Cho Y et al. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br. J. Cancer 98(7), 1258-1263 (2008). (Pubitemid 351481679)
67. + T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27(2), 186-192 (2009).
68. Le Gouvello S, Bastuji-Garin S, Aloulou N et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57(6), 772-779 (2008). (Pubitemid 351716970)
69. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1, E129 (2006).
70. Ling KL, Pratap SE, Bates GJ et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 7, 7 (2007).
71. Michel S, Benner A, Tariverdian M et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br. J. Cancer 99(11), 1867-1873 (2008).
72. + T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 16(16), 4105-4112 (2010).
73. + regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 126(11), 2635-2643 (2010).
74. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 182(3), 318-324 (1997). (Pubitemid 27285785)
75. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998). (Pubitemid 28376536)
76. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006). (Pubitemid 44498003)
77. +) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 33(4), 435-441 (2010).
78. + regulatory lymphocytes induce regression of intestinal tumors in APCMin/+ mice. Cancer Res. 65(10), 3998-4004 (2005). (Pubitemid 40775635)
79. Gounaris E, Blatner NR, Dennis K et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 69(13), 5490-5497 (2009).
80. Clarke AR. Wnt signalling in the mouse intestine. Oncogene 25(57), 7512-7521 (2006). (Pubitemid 44885750)
81. +) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137(4), 1270-1279 (2009).
82. + cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother. 59(5), 653-661 (2010).
83. Zhang B, Jia H, Liu J et al. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J. Immunol. 185(12), 7199-7206 (2010).
84. Bonertz A, Weitz J, Pietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119(11), 3311-3321 (2009).
85. Enarsson K, Johnsson E, Lindholm C et al. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin. Immunol. 118(1), 24-34 (2006). (Pubitemid 43012043)
86. + regulatory T cells originate from both naive T cells and naturally occurring naive-like regulatory T cells. J. Immunol. 180(1), 146-155 (2008).
87. Anz D, Mueller W, Golic M et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int. J. Cancer DOI: 10.1002/ijc.25902 (2011) (Epub ahead of print).
88. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178(4), 2155-2162 (2007). (Pubitemid 46233413)
89. Massague J. TGFb in cancer. Cell. 134(2), 215-230 (2008).
90. +CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172(9), 5149-5153 (2004). (Pubitemid 38542009)
91. + T regulatory cells: role of tumor-derived TGF-β. J. Immunol. 178(5), 2883-2892 (2007). (Pubitemid 46333166)
92. Hindley JP, Ferreira C, Jones E et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 71(3), 736-746 (2011).
93. + T cells. PLoS ONE 5(10), e13623 (2010).
94. + regulatory T cells responsible for protection against diabetes. Proc. Natl Acad. Sci. USA 101(13), 4572-4577 (2004). (Pubitemid 38437452)
95. + T cells. J. Immunol. 173(11), 6526-6531 (2004). (Pubitemid 39541034)
96. + regulatory T cell proliferation. J. Exp. Med. 202(7), 919-929 (2005). (Pubitemid 41396892)
97. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 29(11), 514-522 (2008).
98. + Treg clones obtained from peripheral blood of patients with cancer. Int. J. Cancer 121(11), 2473-2483 (2007). (Pubitemid 350022417)
99. + regulatory T cells. Lab. Invest. 87(6), 582-590 (2007). (Pubitemid 46788787)
100. + T cells to cause regression of an advanced lymphoma. Immunology 71(1), 90-95 (1990). (Pubitemid 20296077)
101. Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J. Immunol. 180(9), 5871-5881 (2008).
102. Mougiakakos D, Johansson CC, Jitschin R, Bottcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 117(3), 857-861 (2011).
103. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113(15), 3542-3545 (2009).
104. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 272(5258), 60-66 (1996). (Pubitemid 26110755)
105. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 12(3), 336-341 (2000). (Pubitemid 30240545)
106. + regulatory T cell homing. Eur. J. Immunol. 37(4), 978-989 (2007). (Pubitemid 46925335)
107. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 108(2), 426-431 (2006). (Pubitemid 44061338)
108. + T-regulatory cell subset has optimal suppressive and proliferative potential. Am. J. Transplant. 4(1), 65-78 (2004). (Pubitemid 38155491)
109. + regulatory T cells bear functional skin-homing receptors. J. Immunol. 177(7), 4488-4494 (2006). (Pubitemid 44469779)
110. + regulatory T cells. J. Exp. Med. 194(6), 847-853 (2001). (Pubitemid 32983019)
111. Ganss R, Arnold B, Hammerling GJ. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 34(10), 2635-2641 (2004). (Pubitemid 39430139)
112. Ryschich E, Schmidt J, Hammerling GJ, Klar E, Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 97(6), 719-725 (2002). (Pubitemid 34106323)
113. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68(14), 5972-5978 (2008).
114. + T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12(8), 1145-1155 (2000). (Pubitemid 30618021)
115. + T regulatory cell-mediated suppression. Immunity 30(5), 636-645 (2009).
116. Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J. Immunol. 175(3), 1456-1463 (2005). (Pubitemid 41023045)
117. + T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32(2), 266-278 (2010).
118. Cao X, Cai SF, Fehniger TA et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27(4), 635-646 (2007). (Pubitemid 47628832)
119. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204(6), 1257-1265 (2007). (Pubitemid 46919862)
120. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4), 1225-1232 (2007). (Pubitemid 47281420)
121. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29(39), 5346-5358 (2010).
122. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review).Int. J. Oncol. 32(3), 527-535 (2008). (Pubitemid 351330458)
123. Mandapathil M, Szczepanski MJ, Szajnik M et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 15(20), 6348-6357 (2009).
124. Kullberg MC, Ward JM, Gorelick PL et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and g interferon-dependent mechanism. Infect. Immun. 66(11), 5157-5166 (1998). (Pubitemid 29044604)
125. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197(1), 111-119 (2003). (Pubitemid 36110262)
126. Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol. 180(1), 55-61 (1997). (Pubitemid 27433618)
127. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929-979 (2004). (Pubitemid 38680445)
128. Shime H, Yabu M, Akazawa T et al. Tumor-secreted lactic acid promotes IL-23/ IL-17 proinflammatory pathway. J. Immunol. 180(11), 7175-7183 (2008).
129. Blatner NR, Bonertz A, Beckhove P et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl Acad. Sci. USA 107(14), 6430-6435 (2010).
130. Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl Acad. Sci. USA 102(2), 419-424 (2005). (Pubitemid 40116782)
131. + regulatory T cells. J. Exp. Med. 201(5), 737-746 (2005). (Pubitemid 40395119)
132. Collison LW, Chaturvedi V, Henderson AL et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11(12), 1093-1101 (2010).
133. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol. Rev. 226, 248-262 (2008).
134. + CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur. J. Immunol. 37(1), 282-291 (2007). (Pubitemid 46128808)
135. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70(20), 7800-7809 (2010).
136. Li X, Kostareli E, Suffner J, Garbi N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40(12), 3325-3335 (2010).
137. + T cell-mediated immunity. J. Exp. Med. 168(6), 2193-2206 (1988). (Pubitemid 19020899)
138. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70(12), 4850-4858 (2010).
139. Malvicini M, Rizzo M, Alaniz L et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res. 15(23), 7256-7265 (2009).
140. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 186(2), 807-815 (2011).
141. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine DOI: 10.1016/j. vaccine.2010.12.063 (2010) (Epub ahead of print).
142. + T lymphocytes. Clin. Exp. Immunol. 150(3), 523-530 (2007). (Pubitemid 350098743)
143. + regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin. Immunol. 136(1), 21-29 (2010).
144. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 59(13), 3128-3133 (1999). (Pubitemid 29316012)
145. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999).
146. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25(3), 207-217 (2002). (Pubitemid 34533310)
147. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005). (Pubitemid 43121851)
148. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120(12), 2723-2733 (2007). (Pubitemid 46651297)
149. Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008).
150. Attia P, Maker AV, Haworth LR, Rogers- Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28(6), 582-592 (2005). (Pubitemid 41533092)
151. Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16(20), 5067-5078 (2010).
152. +CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int. J. Oncol. 34(2), 563-572 (2009).
153. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18(2), 206-213 (2006). (Pubitemid 43327304)
154. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 58(5), 823-830 (2009).
155. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996). (Pubitemid 26102823)
156. Lute KD, May KF Jr, Lu P et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti- CTLA-4 antibodies. Blood 106(9), 3127-3133 (2005). (Pubitemid 41565910)
157. Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28(21), 3485-3490 (2010).
158. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3(12 Pt 2), 2703-2707 (1997). (Pubitemid 28133130)
159. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005). (Pubitemid 41464714)
160. Karlsson M, Marits P, Dahl K et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann. Surg. Oncol. 17(7), 1747-1757 (2010).
161. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239(1), 27-44 (2011).